Login to Your Account

Macrocycle Diary's New Entry: Ensemble Deal with Boehringer

By Randy Osborne
Staff Writer

Thursday, November 1, 2012

By entering a potential $186 million research pact with Ensemble Therapeutics Inc. for synthetic macrocycles, Boehringer Ingelheim GmbH became the latest to place its bet on a newish, challenging approach that could combine the all-in-a-pill possibility of small molecules with the biological bull's-eye talent of large ones.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription